BETHESDA, Md., March 8, 2012 /PRNewswire/ -- Spherix Incorporated (NASDAQ: SPEX) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – announces that Dr. Robert Lodder, Company President, will be making two presentations at the Pittcon Conference to be held March 11-15 in Orlando, FL, at the Orlando Convention Center. Dr. Lodder's presentations discuss two of Spherix's pipeline products and potential indications for use in treating heart disease, dyslipidemia and metabolic syndrome. They are:
- March 12, 2012 – "Molecular Factor Computing (MFC) of the Extent of Atherosclerosis in D‑Tagatose Treatment," in Room 308D at 3:35 p.m.
- March 15, 2012 – "Measurement of Lipoproteins in Treatment with SPX-106," in Room 308C at 10:15 a.m.
MFC uses new high speed integrated computational imaging (ICI) techniques to simplify trials and measure arterial characteristics like reduction in atherosclerotic lesion area with D-tagatose administration quickly and accurately. Other blood vessel anomalies like abdominal aortic aneurysm (AAA), which is often correlated to atherosclerosis, can also be quickly identified and measured. In genetically engineered mice, substitution of tagatose in the diet for sucrose significantly reduced lesion area (p<0.001) in mice over a 16-week study. MFC of macrophage activity and collagen content was also conducted (see Figure 1).
Lipoprotein measurements conducted using fast protein liquid chromatography (FPLC), enzymatic methods, near-infrared and infrared spectrometry show statistically significant reductions (p<0.05) in VLDL, LDL and HDL when SPX106 is administered over 8 weeks with D-tagatose. LDL and oxLDL are correlated to expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), an endogenous inhibitor of MMPs, in human vascular endothelial cells.